Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: Aspirin: Aspirin 150 mg PO daily in addition to standard of care till toxicity or recurrence
Control Intervention1: Standard of care: Standard of care as per guidelines based on the TNM
Sponsors
Banaras Hindu University
Eligibility
Inclusion criteria
Inclusion criteria: All Histologically proven cases of primary oral cancers. Stage T1 to T4, N0 to N3, M0 to M1. Age above 18. Karnofskyâ?? performance status more than 70, ECOG 0 to 2 Hb above 8.0 gm/dL Total count above 4000 cu mm Platelet count above100000 Serum creatinine less than 1.0mg Liver enzymes up to 1.5 times normal Bilirubin less 1.0mg
Exclusion criteria
Exclusion criteria: Patients with acid peptic disease Pregnant and lactating women. Patients not willing to participate. Patients with known allergy to NSAID Patients with Asthma, rhinitis and nasal polyps Presence of viral fever Use of any other blood thinner like warfarin, heparin or low molecular weight heparin bleeding/blood-clotting disorders (such as hemophilia, vitamin K deficiency, low platelet count) pyruvate kinase or G6PD deficiency Patients receiving mifepristone, acetazolamide, corticosteroids, dichlorphenamide, methotrexate, valproic acid, herbal medications (such as ginkgo biloba) Patients with recent history of anti-viral vaccines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety and toxicity as per WHO toxicity criteria and adverse event monitoringTimepoint: Every 3 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival from the time of diagnosis to deathTimepoint: Common closing date of study;Progression free survival from the time of first diagnosis to local recurrence or metastasisTimepoint: At common closing date | — |
Countries
India
Contacts
Public ContactSumithlal
Banaras Hindu University
Outcome results
None listed